Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab and XL888 in Advanced Gastrointestinal Malignancies
NCT03095781Phase 1Completed
- Sponsor
- Emory University
- Start
- Jul 2017
- Primary completion
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of xl888 in gastrointestinal cancer, pancreatic cancer (PC) and colorectal cancer (CRC) (3 arms), sponsored by Emory University. Primary endpoint: Recommended Phase II Dose at Day 22. Started Jul 2017; status: completed.
02
Drugs
xl888
03
Conditions
gastrointestinal cancerpancreatic cancer (PC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT03095781.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03095781.